The Small Biotech Innovation Act exempts qualifying drugs from Medicare's drug price negotiation program starting in 2029 for small biotech manufacturers that meet specific R&D investment thresholds. To qualify, a company must have five or fewer single-source drugs and spend 30% to 70% of its net revenue on research and development (based on the number of drugs), while not being controlled by a foreign government. Manufacturers must apply annually with financial data and certification of R&D spending, and the exemption ends if the company is acquired by a non-qualifying entity after 2029. This directly affects small U.S.-based biotech firms developing innovative drugs, allowing them to avoid price negotiations under Medicare.
The PrEP Access Act expands Medicare Part B coverage to include pharmacist-provided HIV prevention services, such as pre-exposure prophylaxis (PrEP) counseling, medication administration, and related testing. It directly affects Medicare beneficiaries (primarily seniors) and pharmacists, allowing pharmacists to bill Medicare for these services under state law. Key provisions set payment at 80% of the lesser of actual charges or 85% of physician rates, and prohibit balance billing for these services. The policy change takes effect January 1, 2027, making PrEP more accessible through pharmacy settings.
The PBM Reporting Transparency Act requires the Medicare Payment Advisory Commission (MedPAC) to produce two reports analyzing pharmacy benefit manager (PBM) agreements with Medicare prescription drug plans. The first report, due 2 years after data becomes available, must detail trends in PBM contracts, their impact on beneficiaries' out-of-pocket costs and pharmacy reimbursement rates, and include recommendations. A second report, due 2 years after the first, will track changes in this data over time and provide updated recommendations. This legislation directly affects Medicare drug plan participants by increasing transparency around PBM practices that influence prescription drug costs.
This bill mandates a study by the Government Accountability Office (GAO) to examine how specific contract clauses in health insurance agreements affect competition and costs. It focuses on "anti-steering" clauses (restricting insurers from directing patients to lower-cost providers), "anti-tiering" clauses (blocking tiered provider networks), "all-or-nothing" clauses (forcing inclusion of all providers), and "gag" clauses (preventing price transparency). The study will assess these clauses' impact on healthcare consolidation, consumer prices, access, and whether federal agencies have sufficient resources to enforce antitrust laws against them. The findings must be reported to relevant congressional committees within 18 months of the bill's enactment. This is a procedural study - no immediate policy changes are implemented by the bill itself.
This bill reclassifies pharmacy benefit managers (PBMs) as fiduciaries under federal law, requiring them to act in the best interest of group health plans they serve. It mandates PBMs to disclose all compensation sources (including rebates and fees) and prohibits them from shielding themselves from liability for breaches of duty. The law directly affects PBMs, employers offering health plans, and health insurers that use PBM services. Key provisions include new transparency rules, clarifying that PBMs cannot be the "responsible fiduciary" for disclosure purposes, and banning contracts that exempt PBMs from accountability.
This bill modifies how Medicare calculates rebates for certain drugs to potentially lower costs for beneficiaries. It changes the reference year for rebate calculations from 2021 back to 2016 for both Medicare Part B (outpatient drugs) and Part D (prescription drug coverage) programs. The bill also adjusts how drug units are counted for rebates, excluding units paid for through state Medicaid programs or other existing rebate programs. These changes apply to Part B rebates starting January 2026 and Part D rebates starting October 2025. The policy directly affects drug manufacturers who pay Medicare rebates and impacts Medicare beneficiaries through potential cost reductions in covered drugs.
HR 6575, the CommonGround for Affordable Health Care Act, extends enhanced premium tax credits for health insurance through 2026, directly benefiting millions of lower and middle-income Americans purchasing coverage through the ACA marketplace. The bill modifies income thresholds for premium subsidies, creating new income tiers that maintain or increase financial assistance for households earning up to 1,000% of the poverty level. It includes provisions to prevent fraud in health insurance exchanges by imposing civil penalties on agents and brokers who provide false information, and requires transparency in pharmacy benefit manager contracts to improve drug pricing accountability. The legislation also extends the annual open enrollment period for health insurance exchanges for the 2026 plan year, allowing more time for people to enroll or change coverage.
The PBM Disclosure Act clarifies that pharmacy benefit managers (PBMs) and third-party administrators (TPAs) must disclose both direct and indirect compensation they receive for managing pharmacy benefits in employer-sponsored health plans. This requirement directly affects PBMs and TPAs that provide pharmacy benefit management services to health plans. The bill mandates the Department of Labor to issue regulations within 180 days of enactment, which will apply to health plan years beginning six months after publication. The law explicitly clarifies an existing ERISA disclosure rule without creating new requirements.
The PILLS Act creates tax credits to encourage domestic production of generic drugs and biosimilars in the United States. It offers a production credit of 30% (increasing to 35% for final drug production) with an additional bonus for components made with U.S. materials, phasing out after 2033. The bill also provides a separate 25% investment credit for facilities building or expanding production of these drugs, ending for construction after December 31, 2028. To qualify, manufacturers must produce drugs in the U.S., meet FDA compliance requirements, and not be foreign entities of concern. These provisions primarily affect U.S.-based pharmaceutical companies producing generic drugs and biosimilars.
The End Price Gouging for Medications Act establishes annual reference prices for prescription drugs based on the lowest retail prices in 12 international reference countries (like Canada and the UK) or specific criteria if international data is unavailable. It requires drug manufacturers to sell medications at or below these reference prices for all patients covered by federal health programs - including Medicare, Medicaid, TRICARE, and VA care - as well as for all other patients, including those with private insurance. Manufacturers violating this rule face civil penalties of five times the revenue difference, with collected funds directed to the National Institutes of Health for drug research. This bill directly affects drug manufacturers and millions of Americans enrolled in the specified federal health programs.
